MONISTAT 7
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MONISTAT 7 (MONISTAT 7).
Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, reducing ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Minimal systemic absorption after vaginal application; any absorbed miconazole is extensively metabolized in the liver via oxidative pathways and excreted in feces and urine. |
| Excretion | Primarily via feces (approximately 87-93% of dose) as unchanged drug and metabolites; renal excretion negligible (<1%). |
| Half-life | Terminal elimination half-life is approximately 24-30 hours following intravaginal administration; clinical significance: supports once-daily dosing. |
| Protein binding | Approximately 88-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent Vd is approximately 0.25-0.35 L/kg; indicates extensive tissue distribution with high local concentrations at vaginal mucosa. |
| Bioavailability | Intravaginal: Approximately 5-10% systemic absorption of the administered dose; negligible when applied topically. |
| Onset of Action | Intravaginal: Relief of symptoms (itching, discharge) typically begins within 24-72 hours after first dose. |
| Duration of Action | Therapeutic concentrations persist locally for at least 72 hours after a single dose; clinical cure rate >80% after 7-day regimen. |
Intravaginal administration of 100 mg miconazole nitrate suppository once daily at bedtime for 7 days.
| Dosage form | SUPPOSITORY |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment due to limited data. |
| Pediatric use | Not recommended for children under 12 years; for adolescents 12 years and older, same adult dose. |
| Geriatric use | No dose adjustment needed; consider potential for reduced vaginal mucosal integrity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MONISTAT 7 (MONISTAT 7).
| Breastfeeding | Excretion into human milk unknown; M/P ratio not determined. Minimal systemic absorption after intravaginal application (2-4% in non-pregnant women). Use caution; consider risk of oral thrush in infant. |
| Teratogenic Risk | FDA Pregnancy Category C. No evidence of teratogenicity in animal studies at intravaginal doses up to 200 mg/kg/day (maternal toxic doses). No adequate human studies; topical absorption minimal. First trimester: theoretical risk minimal, but avoid if possible; second/third trimester: considered safe for vaginal candidiasis. |
■ FDA Black Box Warning
None.
| Serious Effects |
Known hypersensitivity to miconazole nitrate or any component of the product.
| Precautions | If sensitization or irritation occurs, discontinue use. Patients with known hypersensitivity should avoid use. Discontinue if symptoms persist or recur within 2 months. |
Loading safety data…
| Fetal Monitoring |
| No specific monitoring required. Monitor for local irritation or allergic reaction. In pregnancy, assess for recurrent infection or treatment failure. |
| Fertility Effects | No known adverse effects on fertility in animal or human studies. Not indicated for contraception. |